Recent Intervention Studies with Antihypertensive Drugs and Their Influence on Guidelines;Aktuelle Interventionsstudien zur Hochdrucktherapie und Ihr Einfluss auf Therapieempfehlungen

Medizinische Klinik

Volumn 98, Issue 12, 2003, Pages 771-775

  Rahn, Karl Heinz ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antihypertensive agents; Hypertension; Target blood pressure

Indexed keywords

AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN I; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL; LOSARTAN; RESERPINE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; DRUG CHOICE; ESSENTIAL HYPERTENSION; EXPERT SYSTEM; HEART INFARCTION; HUMAN; INCIDENCE; MEDICAL SOCIETY; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZATION; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; STROKE; SUDDEN DEATH; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHLORTHALIDONE; CLINICAL TRIALS; DEATH, SUDDEN, CARDIAC; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; LISINOPRIL; META-ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RISK; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS;

EID: 0348050466     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1323-4     Document Type: Review

References (16)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
2. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 2003;21:1011-53.
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
4. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
5. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3235-64.
7. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
8. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581-4.
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
10. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
11. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens 2003;21:1055-76.
12. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75.
15. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
16. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.